Clinical Trial

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

Study acronym: XH02
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2026 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04-15 -> 2026-07-15 2026-05-23
minor Completion pushed: 2026-04-30 -> 2026-07-30 2026-05-23
Trial Details
NCT Number NCT07197450
Lead Sponsor Peking Union Medical College Hospital
Conditions Hypoparathyroidism
Enrollment 6 participants
Start Date 2025-05-20
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22